PEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against PepGen, Inc. for allegedly making materially false and misleading statements regarding its business and operations during the specified Class Period [1][3]. Summary by Sections Class Action Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors have until August 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against PepGen - The complaint alleges that PepGen's management made false statements about the effectiveness and safety of PGN-EDO51 [3]. - It is claimed that the CONNECT2 study was either dangerous or deficient for FDA approval, leading to the likelihood of halting the study [3]. - The allegations suggest that PepGen's clinical, regulatory, and commercial prospects were overstated, making public statements materially false and misleading [3]. Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [4][7].